• News
  • BioTech

Lpath withdraws from Pfizer process to assign iSONEP rights

San Diego's Lpath Inc. is no longer actively participating in Pfizer's process to assign the exclusive option it has for a worldwide license to develop and commercialize Lpath's iSONEP, a treatment for wet age-related macular degeneration.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!